Matthew Kurian, Executive Committee Member at KYSCO, shared on LinkedIn:
“4 breast cancer FDA decisions to watch as we close out 2026
- Giredestrant – LidERA
Could change the standard of adjuvant endocrine therapy for the first time in decades. - Giredestrant + everolimus – evERA
A great potential option for those hesitant about simply going from one CDK4/6 inhibitor to another after progression. - Tucatinib + HP – HER2CLIMB-05
I like this for patients who prefer the classic THP induction – come off chemo – maintenance approach, versus DB-09 and essentially continuous T-DXd-based therapy. Especially interesting as we see just how durable responses can be approaching the 2-year mark. - Camizestrant – SERENA-6
Perhaps the most fascinating concept: detect ESR1 resistance in ctDNA and switch therapy before radiographic progression. Could have implications far beyond this one drug.
A lot could still change in breast oncology before 2026 is over. Great overview from CURE.”
You can also read:
FDA Grants Accelerated Approval to Camizestrant for ESR1-Mutated Advanced Breast Cancer
